Phase 1 Anti-HER-2 Vaccine (APC8024) Shows Clinical Benefit

[Paul]

Dendreon's Phase I Results of APC8024 -- anti-HER-2 Therapeutic Vaccine Demonstrate Ongoing Clinical Benefit in Women with Advanced Metastatic Breast Cancer as reported at the American Society of Clinical Oncology 2003 Annual Meeting

[Christine]

Thank you for your prompt article submissiom. I just sent an e-mail to Linda Marker and Dr. Park I thought it was a good idea to introduce our site to these scienyists who may need a future vehicle to work with to link on to our site if the future success of the research permits.